Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
6 pending office actions • 3 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
UNIVERSITÄT ZU KÖLN manages 6 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 6 distinct examiners and 3 distinct art units. DEKARSKE, MADELINE MCGUIRE is the busiest examiner, currently handling 1 busiest examiner pending action. The presence of 6 distinct examiners for 6 pending office actions suggests a decentralized prosecution environment.
Although there are 6 distinct examiners, they are grouped within only 3 distinct art units. This indicates that while the examiners are different, they likely share common supervisory or policy frameworks within their respective units. DEKARSKE, MADELINE MCGUIRE is the busiest examiner with 1 pending action, meaning the workload is evenly split among all assigned officials. Practitioners should look for consistency within the 3 distinct art units even as they navigate the individual preferences of the 6 distinct examiners involved. The 6 pending office actions are spread across these 3 units, requiring a strategy that balances individual examiner styles with unit-wide standards.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (33%) |
| §102 only | 1 (17%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DEKARSKE, MADELINE MCGUIRE | 1 | 0.0% | +0.0% |
| BLUMEL, BENJAMIN P | 1 | 70.8% | +30.5% |
| LUCK, SEAN M | 1 | 62.7% | +27.5% |
| KANE, TREVOR LOGAN | 1 | 69.4% | +52.5% |
| SALMON, KATHERINE D | 1 | 42.8% | +37.9% |
| MOON, MATTHEW RYAN | 1 | 57.7% | +60.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18725502 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | DEKARSKE, MADELINE MCGUIRE | — |
| 18715360 | NEUTRALIZING ANTIBODIES AGAINST SARS-RELATED CORONAVIRUS | BLUMEL, BENJAMIN P | — |
| 18586191 | TOOL AND METHOD FOR DISAGGREGATION OF POLYQ STRETCH-CONTAINING PROTEINS | KANE, TREVOR LOGAN | — |
| 18681429 | METHOD FOR IDENTIFYING RESPONSIVENESS TO FIBROBLAST GROWTH FACTOR RECEPTOR 1 INHIBITOR THERAPY | SALMON, KATHERINE D | — |
| 18562644 | CLOSED INTUBATION SYSTEMS HAVING IMPROVED AIRWAY ACCESS FOR EXAMINATION DEVICES | MOON, MATTHEW RYAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18715360 | NEUTRALIZING ANTIBODIES AGAINST SARS-RELATED CORONAVIRUS | BLUMEL, BENJAMIN P | — |
| 18703581 | METHODS FOR DETECTING A SPECTRUM OF AN ION SPECIES, FOR SEGREGATING A MIXTURE OF A PLURALITY OF ION SPECIES, AND FOR DETERMINING A MIXTURE RATIO OF THE MIXTURE | LUCK, SEAN M | — |
| 18586191 | TOOL AND METHOD FOR DISAGGREGATION OF POLYQ STRETCH-CONTAINING PROTEINS | KANE, TREVOR LOGAN | — |
| 18681429 | METHOD FOR IDENTIFYING RESPONSIVENESS TO FIBROBLAST GROWTH FACTOR RECEPTOR 1 INHIBITOR THERAPY | SALMON, KATHERINE D | — |
| 18562644 | CLOSED INTUBATION SYSTEMS HAVING IMPROVED AIRWAY ACCESS FOR EXAMINATION DEVICES | MOON, MATTHEW RYAN | — |
| Art Unit | Apps |
|---|---|
| 1657 | 1 |
| 1682 | 1 |
| 3785 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18725502 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | DEKARSKE, MADELINE MCGUIRE | — | §103§112DP | Non-Final OA | — | Pending | Jun 28, 2024 |
| 18715360 | NEUTRALIZING ANTIBODIES AGAINST SARS-RELATED CORONAVIRUS | BLUMEL, BENJAMIN P | — | §101§112 | Non-Final OA | — | Pending | May 31, 2024 |
| 18703581 | METHODS FOR DETECTING A SPECTRUM OF AN ION SPECIES, FOR SEGREGATING A MIXTURE OF A PLURALITY OF ION SPECIES, AND FOR DETERMINING A MIXTURE RATIO OF THE MIXTURE | LUCK, SEAN M | — | §102 | Non-Final OA | — | Pending | Apr 22, 2024 |
| 18586191 | TOOL AND METHOD FOR DISAGGREGATION OF POLYQ STRETCH-CONTAINING PROTEINS | KANE, TREVOR LOGAN | 1657 | §102§103§112 | Non-Final OA | — | Pending | Feb 23, 2024 |
| 18681429 | METHOD FOR IDENTIFYING RESPONSIVENESS TO FIBROBLAST GROWTH FACTOR RECEPTOR 1 INHIBITOR THERAPY | SALMON, KATHERINE D | 1682 | §101§102§103§112 | Non-Final OA | — | Pending | Feb 05, 2024 |
| 18562644 | CLOSED INTUBATION SYSTEMS HAVING IMPROVED AIRWAY ACCESS FOR EXAMINATION DEVICES | MOON, MATTHEW RYAN | 3785 | §103§112 | Non-Final OA | — | Pending | Nov 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial